SynthesisBMC women's health2025
Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a Network Meta-Analysis of Randomized controlled trials.
Synthesis in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Effects of GLP-1 Receptor Agonists vs Metformin in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.Cureus · 2026Review
- Modulating endoplasmic reticulum stress and NLRP3 inflammasome in polycystic ovary syndrome: a review of natural and synthetic compounds.Inflammopharmacology · 2025Review
- Identification and validation of biomarkers associated with glycolysis in polycystic ovarian syndrome.Scientific reports · 2025Article
- Associations of Serum GIP, GLP-1, and DPP-4 with Metabolic and Hormonal Profiles and Tobacco Exposure in Women with Polycystic Ovary Syndrome.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolycystic ovary syndrome (PCOS) is a common endocrine disorder associated with metabolic and hormonal abnormalities. This study aimed to evaluate the comparative efficacy of pharmacological interventions on these outcomes.
methodsWe conducted a systematic review and network meta-analysis of randomized controlled trials (RCTs) assessing pharmacological treatments for PCOS. Searches in PubMed, MEDLINE, Embase, and Web of Science were conducted up to October 20, 2023. Eligible studies were RCTs with at least 12 weeks of follow-up and outcomes including body weight (BW), body mass index (BMI), waist circumference (WC), testosterone, sex hormone-binding globulin (SHBG), lipid profiles, HOMA-IR, fasting blood glucose (FBG), and fasting insulin (FINS).
resultsTwenty-nine RCTs with 1476 participants were included. The combination of standard therapy with GLP-1 receptor agonists significantly reduced BW (MD= -3.44; 95% CI= -6.20 to -0.67), BMI (MD= -2.05; 95% CI= -3.55 to -0.55), and WC (MD= -4.39; 95% CI= -6.75 to -2.02) compared to standard therapy alone. Orlistat significantly lowered testosterone (SMD= -2.16; 95% CI= -3.84 to -0.48) and increased HDL-C levels (SMD = 0.90; 95% CI = 0.02 to 1.79) compared to placebo. The combination therapy also reduced HOMA-IR (MD= -1.29; 95% CI= -2.38 to -0.21) and FBG (SMD= -1.80; 95% CI= -3.04 to -0.55) compared to placebo.
conclusionCombining standard therapy with GLP-1 receptor agonists offers superior efficacy in improving metabolic and hormonal outcomes in women with PCOS. Orlistat effectively reduces androgen levels. These findings support the use of combination pharmacotherapy for comprehensive management of PCOS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.